Literature DB >> 32044330

Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism.

Jennifer K Blackburn1, Daniel W Curry2, Anna N Thomsen2, Robert H Roth2, John D Elsworth3.   

Abstract

Paraoxonase-2 regulates reactive oxygen species production in mitochondria. Stimulating its expression has therapeutic potential for diseases where oxidative stress plays a significant role in the pathology. Evidence suggests that the anti-diabetic drug pioglitazone may provide neuroprotection in Parkinson's disease, Alzheimer's disease, brain trauma and ischemia, but the biochemical pathway(s) responsible has not been fully elucidated. Here we report that pioglitazone (10 mg/kg/day) for 5 days significantly increased paraoxonase-2 expression in mouse striatum. Thus, this result highlights paraoxonase-2 as a target for neuroprotective strategies and identifies pioglitazone as a tool to study the role of paraoxonase-2 in brain.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroprotection; Oxidative stress; Paraoxonase-2; Parkinson's disease; Peroxisome proliferator-activated receptor gamma; Pioglitazone; Striatum

Mesh：

Substances：

Year:  2020        PMID： 32044330      PMCID： PMC7089823          DOI： 10.1016/j.expneurol.2020.113234

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


  10 in total

1.  Susceptibility to a parkinsonian toxin varies during primate development.

Authors:  B A Morrow; R H Roth; D E Redmond; S Diano; J D Elsworth
Journal:  Exp Neurol       Date:  2012-02-14       Impact factor: 5.330

Review 2.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

3.  Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis.

Authors:  Asokan Devarajan; Noam Bourquard; Susan Hama; Mohamad Navab; Victor R Grijalva; Susan Morvardi; Catherine F Clarke; Laurent Vergnes; Karen Reue; John F Teiber; Srinivasa T Reddy
Journal:  Antioxid Redox Signal       Date:  2010-09-06       Impact factor: 8.401

4.  Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Authors: 
Journal:  Lancet Neurol       Date:  2015-06-23       Impact factor: 44.182

5.  Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation.

Authors:  Maayan Shiner; Bianca Fuhrman; Michael Aviram
Journal:  Atherosclerosis       Date:  2007-02-12       Impact factor: 5.162

6.  Developmental expression of paraoxonase 2.

Authors:  Jacqueline M Garrick; Khoi Dao; Rian de Laat; John Elsworth; Toby B Cole; Judit Marsillach; Clement E Furlong; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-04-07       Impact factor: 5.192

7.  The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

Authors:  Christine R Swanson; Valerie Joers; Viktoriya Bondarenko; Kevin Brunner; Heather A Simmons; Toni E Ziegler; Joseph W Kemnitz; Jeffrey A Johnson; Marina E Emborg
Journal:  J Neuroinflammation       Date:  2011-08-05       Impact factor: 8.322

8.  Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan.

Authors:  I-Hsun Li; Senyeong Kao; Hsiu-Feng Wu; Li-Ting Kao; Jui-Hu Shih; Hui-Han Kao; Yu-Ching Chou
Journal:  BMJ Open       Date:  2018-08-29       Impact factor: 2.692

9.  DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress.

Authors:  Mohammad Parsanejad; Noam Bourquard; Dianbo Qu; Yi Zhang; En Huang; Maxime W C Rousseaux; Hossein Aleyasin; Isabella Irrcher; Steve Callaghan; Dominique C Vaillant; Raymond H Kim; Ruth S Slack; Tak W Mak; Srinivasa T Reddy; Daniel Figeys; David S Park
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

10.  Glitazone use associated with reduced risk of Parkinson's disease.

Authors:  Brage Brakedal; Irene Flønes; Simone F Reiter; Øivind Torkildsen; Christian Dölle; Jörg Assmus; Kristoffer Haugarvoll; Charalampos Tzoulis
Journal:  Mov Disord       Date:  2017-09-01       Impact factor: 10.338
  10 in total
  11 in total

1.  Expression of PON2 isoforms varies among brain regions in male and female African green monkeys.

Authors:  Sumit Jamwal; Jennifer K Blackburn; John D Elsworth
Journal:  Free Radic Biol Med       Date:  2021-12-07       Impact factor: 7.376

2.  Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders.

Authors:  Jennifer K Blackburn; Sumit Jamwal; Weiwei Wang; John D Elsworth
Journal:  Neurochem Int       Date:  2021-11-09       Impact factor: 3.921

3.  Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis.

Authors:  Mahshid Tahamtan; Iraj Aghaei; Mohammad Shabani; Abbas Nazari; Vahid Pooladvand; Moazamehosadat Razavinasab
Journal:  Metab Brain Dis       Date:  2022-08-09       Impact factor: 3.655

Review 4.  Parkinson's disease treatment: past, present, and future.

Authors:  John D Elsworth
Journal:  J Neural Transm (Vienna)       Date:  2020-03-14       Impact factor: 3.575

Review 5.  PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.

Authors:  Sumit Jamwal; Jennifer K Blackburn; John D Elsworth
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 12.310

6.  Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys.

Authors:  Sumit Jamwal; Jennifer K Blackburn; John D Elsworth
Journal:  Free Radic Biol Med       Date:  2021-03-17       Impact factor: 7.376

7.  Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury.

Authors:  W Brad Hubbard; Malinda L Spry; Jennifer L Gooch; Amber L Cloud; Hemendra J Vekaria; Shawn Burden; David K Powell; Bruce A Berkowitz; Werner J Geldenhuys; Neil G Harris; Patrick G Sullivan
Journal:  Brain       Date:  2021-12-31       Impact factor: 13.501

8.  Insights into the role of paraoxonase 2 in human pathophysiology.

Authors:  Fauzia Parween; Rinkoo Devi Gupta
Journal:  J Biosci       Date:  2022       Impact factor: 1.826

9.  Airway epithelial Paraoxonase-2 in obese asthma.

Authors:  Daniel Efrain Winnica; Anthony Monzon; Shuyu Ye; Eszter K Vladar; Maxwell Saal; Riley Cooney; Cuining Liu; Sunita Sharma; Fernando Holguin
Journal:  PLoS One       Date:  2022-03-14       Impact factor: 3.240

Review 10.  Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?

Authors:  Khalil Mallah; Christine Couch; Davis M Borucki; Amer Toutonji; Mohammed Alshareef; Stephen Tomlinson
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.